3rd Quarter - Report

BIOMET, INC. for BIOMET, INC.

Firm
Client
Income
—
Expenses
$140,000
Expense method
A: Lobbying Disclosure Act definitions

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Medicare/Medicaid MMM

P.L. 111-148, Patient Protection and Affordable Care Act, provisions related to accountable care organizations and gainsharing; Tax policy; FDA 510(k) reform; Medicare Payment Policy including Outpatient Prospective Payment Ruling and the Inpatient Prospective Payment ruling for FY2010.

LobbyistCovered position, as disclosed
WILLIAM C KOLTER —

Contacted: SENATE; Health & Human Services, Dept of (HHS); HOUSE OF REPRESENTATIVES

Medical/Disease Research/Clinical Labs MED

S.3398 Medical Device Safety Act of 2008- all provisions related to federal pre-emption of state laws with respect to Call III devices; S.3408 Comparative Effectiveness Research Act of 2008- all provisions related to establishment of a Health care Comparative Research Institute; and FDA Globalization Act - provisions related to inspection fees and schedules. S. 3408: Comparative Effectiveness Research Act of 2008 - All provisions related to establishment of a Health Care Comparative Research Institute; FDA Globalization Act (draft legislation in House and Senateno bill number yet) - Provisions related to inspection fees and schedules

LobbyistCovered position, as disclosed
WILLIAM C KOLTER —

Contacted: HOUSE OF REPRESENTATIVES; Health & Human Services, Dept of (HHS); SENATE

Bills named: S. 3398 (111th), S. 3408 (111th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.